Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera plus octreotide versus high-dose octreotide in first-line advanced GEP-NETs
2019-001562-15Phase 3Active
- Sponsor
- Advanced Accelerator Applications
- Start
- Jun 2019
- Modality
- Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing Lutathera plus octreotide long-acting with High-dose octreotide long-acting (2 arms). Primary endpoint: Progression-free survival. Started Jun 2019; status: active.
02
Drugs
lutetium Lu 177 dotatateoctreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on 2019-001562-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001562-15.